Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade D 13.54 0.74% 0.10
OMER closed down 0.81 percent on Wednesday, February 19, 2020, on 63 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up
Historical OMER trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.74%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.74%
Bollinger Band Squeeze Range Contraction 0.74%
50 DMA Resistance Bearish -0.07%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.07%
Crossed Above 20 DMA Bullish -0.07%
Pocket Pivot Bullish Swing Setup -0.07%
Bollinger Band Squeeze Range Contraction -0.07%
BB Squeeze Started Range Contraction -0.07%
20 DMA Resistance Bearish 3.20%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Medicine Health Biopharmaceutical Medical Specialties Surgery Inflammation Clinical Trial Disorders Schizophrenia Ophthalmology Clinical Research Wet Age Related Macular Degeneration Movement Disorders Urology Cataract Cognitive Disorders Paroxysmal Nocturnal Hemoglobinuria Surgical Specialties Arthroscopy Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.92
52 Week Low 12.31
Average Volume 396,382
200-Day Moving Average 15.81
50-Day Moving Average 13.56
20-Day Moving Average 13.13
10-Day Moving Average 12.95
Average True Range 0.52
ADX 11.04
+DI 28.27
-DI 24.42
Chandelier Exit (Long, 3 ATRs ) 13.37
Chandelier Exit (Short, 3 ATRs ) 13.86
Upper Bollinger Band 13.96
Lower Bollinger Band 12.31
Percent B (%b) 0.69
BandWidth 12.54
MACD Line -0.16
MACD Signal Line -0.24
MACD Histogram 0.0821
Fundamentals Value
Market Cap 602.15 Million
Num Shares 44.8 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -9.14
Price-to-Sales 11.55
Price-to-Book 0.00
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.13
Resistance 3 (R3) 14.14 13.91 14.02
Resistance 2 (R2) 13.91 13.74 13.91 13.98
Resistance 1 (R1) 13.68 13.63 13.57 13.67 13.94
Pivot Point 13.45 13.45 13.40 13.45 13.45
Support 1 (S1) 13.22 13.28 13.11 13.21 12.94
Support 2 (S2) 12.99 13.17 12.99 12.90
Support 3 (S3) 12.76 12.99 12.87
Support 4 (S4) 12.75